BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 30992297)

  • 1. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
    Cohen JV; Sullivan RJ
    Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
    Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
    Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
    Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of binimetinib for the treatment of mutant cutaneous melanoma.
    Koelblinger P; Dornbierer J; Dummer R
    Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
    Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
    Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.
    Smalley KSM; Forsyth PA
    Pharmacol Res; 2018 Sep; 135():265-267. PubMed ID: 29146209
    [No Abstract]   [Full Text] [Related]  

  • 14. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
    Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
    Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
    Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
    Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
    Kiniwa Y; Okuyama R
    Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
    Babiker HM; Byron SA; Hendricks WPD; Elmquist WF; Gampa G; Vondrak J; Aldrich J; Cuyugan L; Adkins J; De Luca V; Tibes R; Borad MJ; Marceau K; Myers TJ; Paradiso LJ; Liang WS; Korn RL; Cridebring D; Von Hoff DD; Carpten JD; Craig DW; Trent JM; Gordon MS
    Invest New Drugs; 2019 Aug; 37(4):636-645. PubMed ID: 30264293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
    Giugliano F; Crimini E; Tarantino P; Zagami P; Uliano J; Corti C; Trapani D; Curigliano G; Ascierto PA
    Cancer Treat Rev; 2021 Sep; 99():102253. PubMed ID: 34186441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.